The FDA accepted a supplemental new drug application to expand the indication for Ryzumvi to include the treatment of ...

Viatris Inc. (NASDAQ:VTRS) is one of the most undervalued stocks under $30 to buy. On February 25, Viatris announced that the ...

FDA PDUFA Goal Date Set for October 17, 2026RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, ...

Did you know that with the passage of time our sight fails more and more? However, there is a new prescription eye drop approved by the U.S. that promises to ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for ...

- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 PONTE VEDRA, Fla., Feb. 21, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. I’ve said it before: There are four stages of life.

TECLens treated the first patient in a first-in-human trial assessing safety and efficacy of qCXL-based refractive correction ...

The MarketWatch News Department was not involved in the creation of this content. The launch of emerging therapies, such as LNZ100 by Lenz Therapeutics, Phentolamine Ophthalmic Solution 0.75% by ...

TearOptix, Inc., a pioneering contact lens company developing advanced solutions for patients with presbyopia, today announced the completion of a strategic corporate financing round led by investors ...

Vuity contracts the iris sphincter muscle, constricting the pupil to improve near and intermediate visual acuity. The Food and Drug Administration (FDA) has approved the supplemental New Drug ...

FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that ...